

LANTHEUS MEDICAL IMAGING, INC.

Customer Billing Transition – Frequently Asked Questions (FAQ)

Executive Summary

Lantheus is consolidating all billing functions for Lantheus-branded products under direct company control. Going forward, invoices will be issued by **Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Medical Imaging, Inc.** This shift replaces prior billing activity performed by Sofie Biosciences and reflects Lantheus' broader effort to simplify operations, ensure data integrity, and scale effectively.

This transition enables:

- One point of contact for all billing, invoicing, and payment inquiries
- Aligned order-to-cash processes across fulfillment, invoicing, and collections
- More accurate billing, faster resolution, and improved internal controls

This is an administrative change only. Product pricing, commercial agreements, order fulfillment processes, **credit approvals, and unused dose credit procedures** remain unchanged. Supporting documents, updated remittance details, and a clear onboarding checklist are included in this communication.

1. What exactly is changing?

- Invoices for Lantheus products will now be issued by **Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Medical Imaging, Inc.**
 - Customers must remit payment using new Lantheus banking details
 - Sofie Biosciences will no longer issue invoices related to Lantheus product orders
-

2. Why is this change being made?

This transition aligns with Lantheus' enterprise strategy to:

- Consolidate financial operations under a single legal entity
- Strengthen end-to-end data integrity across the order-to-cash process
- Enhance billing accuracy and responsiveness

- Build scalable, compliant infrastructure for diagnostics, therapeutics, and theranostics
-

3. Will my service, contract, pricing, or credit process change?

No. This change does **not** affect:

- Contract terms or pricing
- How you place or receive orders
- Your commercial contacts at Lantheus or Sofie
- **Credit approvals or the unused dose credit process**

Only the billing entity and remittance instructions are changing.

4. What do I need to do?

Please take the following actions:

Vendor Setup

- Add **Progenics Pharmaceuticals Inc.** to your vendor master
- Use the provided W-9 and banking information

Banking Update

- Begin using the new remittance instructions for ACH, wire, or check payments

Reconcile Sofie Invoices

- Pay any outstanding invoices from Sofie directly to Sofie using their original remit-to details
- **To prevent duplicate payments, only pay the entity listed on the invoice (either Sofie or Lantheus)**

Issue New POs (if required)

- If your system requires it, issue updated purchase orders to **Progenics Pharmaceuticals Inc.**

Communicate Internally

- Notify your AP, procurement, and finance teams of the changes and updated billing contacts
-

5. What will Lantheus invoices include?

Invoices from Lantheus will display:

- Detailed product descriptions, quantities, and unit pricing
 - Bill-to and ship-to details
 - Updated Lantheus banking instructions
 - Contact information for billing questions and escalations
 - **Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Medical Imaging, Inc.**, listed as the billing entity
-

6. Who should I contact for billing support?

Lantheus Billing Support

Phone: 1-800-964-0446

Email: CSPYL@lantheus.com

Support Hours: Monday to Friday, 8:00 AM – 8:00 PM EST

For urgent needs, email with “URGENT” in the subject line or contact your Lantheus Account Manager.

7. What about open Sofie invoices?

Any invoice issued by Sofie prior to your transition remains their responsibility. Lantheus cannot accept or apply payments meant for Sofie.

To ensure clarity:

- Pay open Sofie invoices using their existing instructions
- Separate Sofie and Lantheus balances in your AP system
- **Do not send payments for Sofie-issued invoices to Lantheus**
- For questions about Sofie invoices, please contact billing@sofie.com

8. Do I need to amend my contract?

No. This change does not require contract changes, re-signing, or addenda. Your agreements and commercial terms remain in effect.

9. Who can help with setup or documentation?

If you need any of the following, please contact CSPYL@lantheus.com or your Account Manager:

- W-9 and remittance letters
 - Sample invoices
 - Vendor onboarding confirmations
 - **Lantheus' EIN: 13-3379479 (as shown on the W-9)**
 - **Formal confirmation letters or documentation to support SOX, audit, or internal compliance requirements**
-

10. Summary Checklist for Customers

- Add **Progenics Pharmaceuticals Inc.** as a new vendor
 - Use updated banking details for all Lantheus invoice payments
 - Pay any open Sofie invoices via their current process
 - Issue new POs if your system requires it
 - Notify your internal stakeholders of the new billing contacts and payment flow
-

Remittance Instructions

Banking Information for Progenics Pharmaceuticals Inc. (a subsidiary of Lantheus Medical Imaging, Inc.):

ACH Payments

Routing Number: 021000021

Account Number: 661509999

Account Name: Progenics Pharmaceuticals Inc.

Wire Transfers

Routing Number: 021000021

SWIFT Code: CHASUS33

Bank: JPMorgan Chase, New York, NY 10017

Account Number: 661509999

Account Name: Progenics Pharmaceuticals Inc.

USPS Check Delivery

Progenics Pharmaceuticals, Inc.

P.O. Box 735664

Dallas, TX 75373-5664

Overnight Courier Check Delivery

JPMorgan Chase (TX1-0029)

Attn: Progenics Pharmaceuticals, Inc. & 735664

14800 Frye Road, 2nd Floor

Fort Worth, TX 76155

Lantheus Medical Imaging, Inc.

In collaboration with Sofie Biosciences

Thank you for your continued partnership. We're here to support you every step of the way.